To read the full article sign up for free or sign in.

Moderna tops public biopharma raises with $1.34B to help fund its COVID-19 vaccine

May 19, 2020

Representing the highest amount ever raised by a public biopharma company on a U.S. exchange, Moderna Inc. priced a $1.34 billion follow-on offering to help fund worldwide manufacturing and distribution of its mRNA-1273 vaccine for COVID-19.

BioWorld Financings Coronavirus Vaccine Follow-on

Data needed for Chinese COVID-19 vaccines against Delta variant

BioWorld Asia

The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study...

Data needed for Chinese COVID-19 vaccines against Delta variant

BioWorld

The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study...

Today's news in brief

BioWorld

BioWorld briefs for August 3.

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for Aug. 3.

Business people with hands atop a digital globe

Mologic acquired by philanthropists to become social enterprise

BioWorld MedTech

LONDON – U.K. rapid diagnostics specialist Mologic Ltd. has been acquired by a group of philanthropists led by George Soros’ Economic Development Fund and the...